Nanjing, China, November 24, 2020 — Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) recently unveiled Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®) at the Brazilian Society of Hemodynamics and Interventional Cardiology Annual Congress (Semana SBHCI 2020), held virtually from November 2–6th 2020. The event was attended by around 2,000 experts and professionals in the field of cardiovascular interventions from more than 30 countries and covered the latest developments in the industry and academia.
On the morning of November 6th, Prof. Chen Shaoliang, Prof. Zhang Junjie, Prof. Ye Fei and Dr. You Wei from the Department of Cardiology, Nanjing First Hospital, presented two interventional procedure cases live on complex coronary bifurcation lesions, which were skillfully performed. The characteristics of the lesions were identified using the criterion for complex bifurcation lesions, which was proposed by Prof. Chen and provides strong clinical guidance for distinguishing between simple bifurcation lesions and complex ones. The team completed the procedures successfully using DK-CRUSH invented by Prof. Chen. The Firehawk® stent was selected in both procedures, being recognized by the experts at the conference for its excellent crossability during procedures and its superior vessel wall apposition.
Prof. Ricardo A. Costa, Chairman of the Congress, who is based in the host country of Brazil, spoke highly of the outstanding performance of the cardiology team of Nanjing No. 1 Hospital, and fully recognized the clinical performance of the Firehawk® stent.
As one of the most important markets in South America, Brazil has an enormous market potential for medical devices and a high demand for cardiovascular interventional products. Under this backdrop, Microport® products such as the Firehawk® Stent and the Firefighter™ Balloon Catheter have received trust and recognition from doctors and patients for their use in Brazil. Microport® will continue to serve as an academic exchange platform for more cardiovascular interventional physicians in Brazil and South America and contribute to the development of local cardiovascular interventional therapies, providing more integrated medical solutions that extend and reshape patients’ lives.